From Recent Issues

Genetics of Prostate Cancer

Abstract: Prostate cancer is a highly heritable cancer, with contributions from rare pathogenic variants in prostate cancer predisposition genes (eg, HOXB13, BRCA2) and from common genetic […]

Update on PARP Inhibitors for the Treatment of Ovarian Cancer

Abstract: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors (PARPis) were first granted US Food and Drug Administration (FDA) approval for ovarian cancer. Trials have focused on high-grade serous […]

Targeting RAS in Gastrointestinal Malignancies

Abstract: Kirsten rat sarcoma virus (KRAS) is one of the prevalent oncogenic drivers in gastrointestinal (GI) cancers, including pancreatic ductal adenocarcinoma and colorectal cancer. The KRAS […]

Supplements

Modern Approaches in Neuroendocrine Tumors (NETs)

In the Clinic: Case Studies The following 2 patient cases highlight the clinical complexity of neuroendocrine tumors (NETs), and the widely different approaches in pancreatic NETs […]

Achieving Durable Response With the TRK Inhibitor Larotrectinib, and Possible Discontinuation of Therapy in Pediatric NTRK Gene Fusion–Positive Solid Tumors

In the Clinic: Case Studies In our clinic, the majority of pediatric patients presenting with neurotrophic tyrosine receptor kinase (NTRK) fusion–positive solid tumors are children diagnosed […]

Highlights in Renal Cell Carcinoma From the American Society of Clinical Oncology Genitourinary Cancers Symposium

A Review of Selected Presentations From the ASCO GU Symposium • February 13-15, 2025 • San Francisco, California Cabozantinib in Combination With Nivolumab and Ipilimumab in […]